From: The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso
Respondent categories | N | Interview type | ||
---|---|---|---|---|
Ouaga | Bobo | |||
Policy maker | National Agency for Pharmaceutical Regulation “Agence Nationale de la Regulation Pharmaceutique” (ANRP) | 2 | – | Interview |
National Malaria Control Program (PNLP) | 3 | – | Interview | |
Regional health authority | 2 | 1 | Interview | |
Malaria researchers | 2 | 1 | Interview | |
Drug wholesaler and retailer | Public sector wholesalers | 3 | – | Interview |
Private sector wholesalers | – | 6 | Interview | |
Public sector retailers | – | 2 | Interview | |
Private sector retailers | 1 | 2 | Interview | |
Drug end user | Public sector health care providers | 1 | 3 | Interview |
Community based health workers | – | 1 | FGD | |
Private sector health care providers | 5 | 3 | Interview | |
Parents/Caregivers | – | 5 | FGD |